Wuhan Hiteck Biological Pharma Co Ltd (300683) — Cash Flow-to-Debt Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of CN¥-17.49 Million could theoretically repay 0% of its total liabilities (CN¥393.09 Million) in one year. See Wuhan Hiteck Biological Pharma Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Wuhan Hiteck Biological Pharma Co Ltd across 12 annual periods. Also explore net asset growth rate of Wuhan Hiteck Biological Pharma Co Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
Year-by-year debt coverage analysis for Wuhan Hiteck Biological Pharma Co Ltd. For market capitalisation and broader financial context, see market cap of Wuhan Hiteck Biological Pharma Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | CN¥22.69 Million | CN¥525.05 Million | ▲ +286.8% |
| 2023 | 0.01x | CN¥5.31 Million | CN¥475.73 Million | ▼ -92.2% |
| 2022 | 0.14x | CN¥53.03 Million | CN¥371.20 Million | ▲ +318.9% |
| 2021 | 0.03x | CN¥12.09 Million | CN¥354.46 Million | ▲ +179.9% |
| 2020 | -0.04x | CN¥-19.70 Million | CN¥461.62 Million | ▼ -127.7% |
| 2019 | 0.15x | CN¥63.03 Million | CN¥409.03 Million | ▼ -6.4% |
| 2018 | 0.16x | CN¥73.42 Million | CN¥445.77 Million | ▼ -47.3% |
| 2017 | 0.31x | CN¥83.08 Million | CN¥265.62 Million | ▼ -27.0% |
| 2016 | 0.43x | CN¥143.86 Million | CN¥335.87 Million | ▼ -26.1% |
| 2015 | 0.58x | CN¥159.89 Million | CN¥275.74 Million | ▲ +13.4% |
| 2014 | 0.51x | CN¥135.40 Million | CN¥264.78 Million | ▲ +24.1% |
| 2013 | 0.41x | CN¥76.82 Million | CN¥186.42 Million | — |